A Comparative Study Efficacy of Trametinib (CT) in Comparison With Trametinib (MEKINIST) in Patients With BRAF V600E or V600K Mutation-positive Solid Tumors

Trial Profile

A Comparative Study Efficacy of Trametinib (CT) in Comparison With Trametinib (MEKINIST) in Patients With BRAF V600E or V600K Mutation-positive Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Sep 2015

At a glance

  • Drugs Trametinib (Primary)
  • Indications Solid tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 May 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 03 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top